From the last shareholders letter:
Quote:The company is also preparing a safety manuscript summarizing the safety data in almost 1,600 patients who have now been treated with leronlimab in CytoDyn-sponsored studies.
Hence my urgency to get this done. Then we don’t have to include disclaimers like stating safety has yet to be proven.